To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
Patient Power Research presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting showed lower rates of CLL patients receiving certain fungal infections if Bruton tyrosine kinase (BTK) inhibitors were part of their treatment plan, versus CLL patients who did not have BTK inhibitors as part of their therapy. Dipenkumar Modi, M.D. , hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidiscipl...
Patient Power Chronic lymphocytic leukemia (CLL) is one of the most common cancers that can be caused by POT1 tumor predisposition syndrome (POT1-TPDS). According to Dipenkumar Modi, M.D. , hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos, POT1-TPDS is found in about 5% of patients who have CLL. This is a hereditary mutation, and there is a 50% chance per child that a parent wit...
Patient Power Nodular sclerosis Hodgkin lymphoma (NSHL) is the most common type of classical Hodgkin lymphoma (cHL), a cancer of the lymphatic system. Dipenkumar Modi, M.D. , hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos, describes the different ways to treat NSHL and its generally favorable prognosis. Read the article here .
ASH Abstract Achievement Award- 2017
Young Investigator Travel Grant Recipient, Society of Hematologic Oncology (SOHO) Annual Meeting- 2017
Recognition Award, Wayne State University 2016 In the area of Citizenship And Academic Achievement
Clinical Research Award, Wayne State University - 2015
Young Achiever Award, American College of Physicians National Conference- 2014